Compare Invesco DB Oil Fund (DBO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Oil Fund vs State Street SPDR S&P Biotech ETF — how do they compare? Invesco DB Oil Fund trades at $24.17 (market cap $255.13M), while State Street SPDR S&P Biotech ETF trades at $154.01 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 39.6× Invesco DB Oil Fund's market cap, and Invesco DB Oil Fund is more actively traded (562,167 versus 12,903,266). Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Oil Fund for 31 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| DBO | XBI | |
|---|---|---|
Market Cap | $255.13M | $10.11B |
Volume | 562,167 | 12,903,266 |
Sector | Commodities - Energy | Broad Market / Factor |
52-Week High | $26.35 | $169.55 |
52-Week Low | $11.98 | $104.99 |
Typical Hold Time | 31 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBO trades at $23.54, down 0.42% on the day, with technical indicators showing a neutral to bearish bias. The stock faces resistance at $24 and support at $23, while moving averages signal bearish momentum. Recent oil market developments, including Middle East tensions and OPEC+ production decisions, create a volatile backdrop for energy stocks.
The outlook remains cautious given geopolitical risks and mixed oil price signals. Investment opportunities exist if supply disruptions persist, but risks include potential price declines from strategic reserve releases and ongoing legal challenges facing the oil industry.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Invesco DB Oil Fund
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
